CORT · Corcept Therapeutics Incorporated — research history
Complete research history. Every dossier, draft, kill, publish, and lesson the system has produced on CORT. Public so users can audit, AI can re-reference. Live price refreshes every 60s.
About CORT · Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. It also develops relacorilant, a selective cortisol modulator for patients with hypercortisolism; a selective cortisol modulator miricorilant, which is in Phase 1b trial for metabolic dysfunction-associated steatohepatitis; and a portfolio of proprietary selective cortisol modulators, such as relacorilant, nenocorilant, miricorilant, and dazucorilant for the treatment of Lou Gehrig's disease. The company was incorporated in 1998 and is headquartered in Redwood City, California.
Live Quote
HOLD (score -1) · 12-1 mom -22.2% · RSI 71.7 · above_both · -11.6% from high
Targets blend Wall Street consensus (5 analysts: low $50.00 / mean $88.00 / high $135.00) with chart-derived floors and ceilings.
1-Year Chart · RSI · MACD
Research Timeline
Newest first. Each entry shows what stage produced it, the verdict/decision, and the reasoning.
Corcept has two approved drugs — Korlym for Cushing's syndrome and Lifyorli (relacorilant+nab-paclitaxel) FDA-approved March 2026 for platinum-resistant ovarian cancer. The NDA resubmission plan for relacorilant's Cushing's indication post-December 2025 CRL is the live catalyst, with a PDUFA date of July 11, 2026 on the original filing still active. Insiders have been sellers into recent price strength — CEO Sean Maduck sold ~$4.87M via 10b5-1 plan in late May at $65-66; other insiders received option grants (no cash outlay). Options flow shows a bearish put/call ratio of 12.64 with net dollar bias -52%. The stock is extremely overbought (RSI 84) and ~24% off its 52-week high of $91, priced at a forward P/E of ~27.9x on Q1 losses. No open-market purchase transactions were found among the recent Form 4s — all cash transactions were either pre-planned sales or option grants to directors.